AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|
16.8 C
New York
Wednesday, September 16, 2026

Tag: progress

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025

BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation...

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

Leuven, Belgium, June 12, 2025AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

Uniting for Impact: “United Against Dengue” Collaboration Launches to Elevate Education, Advocacy and Support across Asia

Led by The International Federation of Red Cross and Red Crescent Societies and Takeda, the regional collaboration is dedicated to supporting the World Health Organization...

UK leads G7 countries in addressing child sexual violence, but ODA cuts are hurting progress

An assessment of five indicators illuminate how the world’s richest nations are addressing the global crisis of childhood sexual violence, UK leads the way

Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that the Company has received a clinical trial notice...

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the...

Argo Named to Fast Company’s 2025 World Changing Ideas List for Smart Routing™ Transit Platform

Vertically integrated transit solution recognized for transforming urban mobility and creating more equitable, sustainable cities TORONTO, June 11, 2025 /CNW/ - Argo Corporation (TSXV: ARGH) (OTCQX:...

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

APP Group Strengthens Japan-Indonesia Economic Ties Through Sustainable Development

JAKARTA, Indonesia, June 12, 2025 /PRNewswire/ -- As Japan accelerates its Green Growth Strategy to achieve carbon neutrality and economic sustainability, APP Group is...

Community Healthcare Trust Releases 2024 Corporate Sustainability Report

FRANKLIN, Tenn., June 11, 2025 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) (the "Company") today announced the release of its second Corporate Sustainability...

National Corporate Housing Releases Annual Corporate Social Responsibility Report Celebrating 25 Years Of Positive Impact

GREENWOOD VILLAGE, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- National Corporate Housing has released its annual Corporate Social Responsibility Report that showcases the company’s commitment to focusing on people, operating sustainably, and enriching community.

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board of Directors

Noted pharmaceutical industry executive Frederick Beddingfield, MD, PhD, has joined the Neurodon Board of Directors, bringing years of industry leadership.

Renée James will join Portland General Electric board of directors, effective June 11, 2025

PORTLAND, Ore., June 11, 2025 /PRNewswire/ -- Renée James has been appointed to the Portland General Electric (NYSE:POR) ("PGE" or the "Company") board of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgress